

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 1 of 3

Application Number **10/509069**

Filing Date

**First Named Inventor**

Lesage et al.

### **Group Art Unit**

**Examiner Name**

Attorney Docket Number

**JAB-1703**

## U.S. PATENT DOCUMENTS

no class	or
subclass	
listed	

## FOREIGN PATENT DOCUMENTS

no class	on
subclass	
listed	

Examiner Signature	/Melissa Perreira/	Date Considered	12/22/2006
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**

DT09 Rec'd PCT/PTO 24 SEP 2004

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Application Number	10/509069
Filing Date	
First Named Inventor	Lesage et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1703

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
MP		Stone T.W., "Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection," Trends in Pharmacological Sciences, Elsevier Trends Journal, vol. 21, no. 4, April 2000, pp. 149-154	
MP		Sing-Yuen S et al., "3-Hydroxy-quinolin-2-ones: inhibitors of HI-glycine binding to the site associated with the NMDA receptor," Bioorganic & Medicinal Chemistry Letters, vol. 6, no. 5, 5 March 1996, pp. 499-504	
MP		Dabhi T.P. et al., "Potential antimicrobial Agents: Synthesis of N,N-Diaryl/N,N-Dialkyl/N-Aryl-N-Alkyl-(2-Aryl/Styryl-6-Acetylquinolin-4-YL)-Formadies," Indian Journal of Heterocyclic Chemistry, vol. 2, no. 2 October 1992 (pp.137-138)	
MP		Bhatt D.J. et al., "Studies on Chalcones: Preparation and Antimicrobial Activity of 2-aryl-4-carboxy-6-acetylquinoline and 2-aryl-4-carboxy-6-benzalacetquinolines," Journal of the Indian Chemical Society, The Indian Chemical Society, vol. 61, no. 9, September 1984, pp. 816-818	
MP		Mutel Vincent et al., "Characterization of (3H) quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections," Journal of Neurochemistry, vol. 75, no. 6, Dec. 2000, pp. 2590-2601	
MP		Peng C. T. et al., "An Evaluation of Different Methods for Tritium Labelling," Fusion Technology, American Nuclear Society, vol. 21, no. 2, pt. 2, pp. 307-311, 1 March 1992	
MP		Brundish et al., "Tritium labeling by selective debromination," Journal of Labelled Compounds and Radio pharmaceuticals, Sussex, GB, vol. 25, no. 12, 1988, pp. 1361-1369	
MP		Thomsen et al., "A Pharmacological characterization of the mGluR1 $\alpha$ subtype of the metabotropic glutamate receptor expressed in a cloned baby hamster kidney cell line," Brain Res. 619:22-28, 1993	
MP		Kingston, A.E., et al., "Sulphur-containing amino acids are agonists for group 1 metabotropic receptors expressed in clonal RGT cell lines," Neuropharmacology 37:277-287, 1998	
MP		Mutel at al., "Characterization of [3H] Quisqualate Binding to Recombinant Rat Metabotropic Glutamate 1a and 5a Receptors and to Rat and Human Brain Sections," J. Neurochem. 75:2590-2601, 2000	
MP		Scott, W.J. et al., "Palladium-Catalyzed Coupling of Vinyl Triflates with Organostannanes. A short Synthesis of Pteraplysin-1," J. Am. Chem. Soc., 1984, 106, 4630	
MP		Lavreysen et al., "Supersensitivity of Human Metabotropic Glutamate 1a Receptor Signaling in L929SA Cells," Mol. Pharmacol. 61:1244-1254, 2002	
MP		Cheng et al., "Relationship Between the Inhibition Constant (K <sub>i</sub> ) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I <sub>50</sub> ) of an Enzymatic Reaction," Biochem. Pharmacol. 22, 3099-3108, 1973	

Examiner Signature	/Melissa Perreira/	Date Considered	12/22/2006
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

OT09 Rec'd PCT/PTO 24 SEP 2004

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Application Number	
Filing Date	10/509069
First Named Inventor	Lesage et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1703

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
MP		Litschig et al., "CPCOEt, a Noncompetitive Metabotropic Glutamate Receptor 1 Antagonist, Inhibits Receptor Signaling Without Affecting Glutamate Binding," <u>Molecular Pharmacol.</u> 55:453-461, 1999	
MP		Zhu et al., "The Competitive and Noncompetitive Antagonism of Receptor-Mediated Drug Actions in the Presence of Spare Receptors," <u>J.Pharm. Tox. Meth.</u> 29:85-91, 1993)	
MP		Carroll et al., "BAY36-7620: A Potent Non-Competitive mGlu1 Receptor Antagonist with Inverse Agonist Activity," <u>Mol. Pharmacol.</u> 59:965-973, 2001	
MP		Hermans et al., "Reversible and non-competitive antagonist profile of CPCOEt at the human type 1a metabotropic glutamate receptor," <u>Neuropharmacology</u> 37:1645-1647, 1998	
MP		van de Waterbeemd et al., "Molecular electrostatic Potential of Orthopramides: Implications for Their Interaction with the D-2 Dopamine Receptor," <u>J.Med. Chem.</u> 29:600-606, 1986	
MP		Schoepp et al., "1S,3R-ACPD-sensitive (metabotropic) [ <sup>3</sup> H]glutamate receptor binding in membranes," <u>Neurosci. Lett</u> 145:100-104, 1992	
MP		Wright et al., "Distribution and Ontogeny of 1S,3R-1-Aminocyclopentane-1,3-Dicarboxylic Acid-Sensitive and Quisqualate-Insensitive [ <sup>3</sup> H]Glutamate Binding Sites in the Rat Brain," <u>J. Neurochem.</u> 63:938-945, 1994	
MP		Lujan et al., "Perisynaptic Location of Metabotropic Glutamate Receptors mGluR1 and mGluR5 on Dendrites and Dendritic Spines in the Rat Hippocampus," <u>Eur.J.Neurosci.</u> 8:1488-1500, 1996	
MP		Shigemoto et al., "Differential Presynaptic Localization of Metabotropic Glutamate Receptor Subtypes in the Rat Hippocampus," <u>J. Neurosci.</u> 17:7503-7522, 1997	
MP		Martin et al., "Cellular Localization of a Metabotropic Glutamate Receptor in Rat Brain," <u>Neuron.</u> 9:259-270, 1992	
MP		Ferraguti et al., "Immunohistochemical Localization of the mGluR1 $\beta$ Metabotropic Glutamate Receptor in the Adult Rodent Forebrain: Evidence for a Differential Distribution of mGluR1 Splice Variants," <u>J. Comp. Neur.</u> 400:391-407, 1998	

Examiner Signature	/Melissa Perreira/	Date Considered	12/22/2006
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.